Based on the information provided, you may not meet the requirements for this study. We want to thank you for your interest – patient volunteers and their family members are an essential part of the development of new therapies for cancer. If you still would like to learn more about Red Cell Therapeutics™ and receive updates about clinical trials that might be available in your area for the potential treatment of cancer for yourself or a loved one, sign up here.
Someone from our Patient Advocacy Team may reach out to you to determine your interest and if you would meet the requirements to be evaluated by a study doctor for screening in the RTX-321 study. Your personal information, including information entered previously and discussed with our Patient Advocacy Team, may then be shared with a clinical study site.
for the potential treatment of human papillomavirus (HPV) 16-associated cancers, including cervical cancer, anal cancer and head and neck cancer (including nasal cavity cancer, oral cancer, laryngeal cancer, hypopharyngeal cancer, nasopharyngeal cancer, and oropharyngeal cancer).
RTX-321 is an investigational cellular therapy that is being evaluated in a Phase 1 clinical trial for the treatment of patients with HPV 16-associated cancers, including cervical cancer, anal cancer and head and neck cancer (including nasal cavity cancer, oral cancer, laryngeal cancer, hypopharyngeal cancer, nasopharyngeal cancer, and oropharyngeal cancer). RTX-321 is engineered to express cancer-fighting molecules and specific proteins, known as antigens, on the cell’s surface. These antigens that are bound to the cell surface may selectively instruct only the cells of the immune system with the ability to potentially recognize and attack the tumor.
Rubius Therapeutics is now enrolling patients in a phase 1 clinical trial of RTX-321 for the treatment of patients with HPV 16-associated cancers, including anal cancer.
Complete a patient screener to see if you may be able to participate.
